Dendritic Cell-Based Immunotherapy in Patients with Resected Pancreatic Cancer: A Promising Strategy for Preventing Recurrence
Discover the promising potential of dendritic cell-based immunotherapy for preventing recurrence in patients with resected pancreatic cancer. A groundbreaking phase I/II clinical trial demonstrates that this immunotherapy approach significantly improves two-year recurrence-free survival (64%) and overall survival (83%) in patients who have undergone surgery and standard chemotherapy. By activating the body’s immune system to target remaining cancer cells, this strategy offers a new, safe, and effective post-surgical option for pancreatic cancer therapy.
The Effectiveness of Dendritic Cell Therapy on Prostate Cancer at Immucura
Prostate cancer is a widespread health concern globally, impacting a significant number of individuals, particularly men. According to recent statistics from the World Health Organization (WHO), prostate cancer remains one of the most common cancers among men, with an estimated 1.4 million new cases reported in 2020. However, there is hope on the horizon with innovative approaches like Dendritic Cell Therapy (DCT). This article delves into the statistics at Immucura related to prostate cancer and explores the efficacy of Dendritic Cell Therapy in its cure, additionally drawing insights from WHO data.
Improved Survival in Stage IV Breast Cancer with DCT
The study aimed to assess the impact of immunotherapy in 368 patients with stage IV breast cancer. The patients were divided into two groups: one receiving a combination of DC-CIK immunotherapy after low-dose chemotherapy, and the other receiving chemotherapy alone (the control group).
Combining DCT with Chemotherapy in Metastatic Prostate Cancer: Phase I/II Clinical Trial
In this study, researchers present the results of a Phase I/II clinical trial conducted on patients with metastatic castration-resistant prostate cancer (mCRPC). The trial focused on a novel approach using docetaxel in combination with autologous mature dendritic cells (DCs) that were specially treated with killed LNCaP prostate cancer cells (DCVAC/PCa).
Triple Negative Breast Cancer: pDC vs. cDC | STUDY
The groundbreaking findings showed that high levels of pDC were significantly associated with improved survival in triple negative breast cancer (TNBC), whereas cDC did not show the same correlation.
Unraveling Dendritic Cells in Glioblastoma Immunotherapy
Glioblastoma (GBM), a devastating primary brain cancer, remains a formidable challenge with a median survival of less than 15 months despite current standard treatments of surgery, radiation, and chemotherapy.
